> Home > Investors > Annual Review 2007 > Focus on our pipeline

Key late stage pipeline compounds

GSK has a full and diverse pipeline, comprising 157 projects in clinical development of which 118 are new chemical entities or new vaccines. Our significant late stage projects are highlighted here, comprising both new chemical entities and new combinations and formulations of existing assets.

> See our full pipeline

From molecule to medicine
 The journey from molecule to medicine is long and challenging. Once we have completed computer and laboratory testing and are confident that we have a potentially active molecule that may impact a disease, we move into clinical studies. This process follows a series of tightly-controlled stages, or phases, with the safety of patients paramount at all times.


Therapeutic area
Key:
 Phase III phrase3
 Phase III trials gather further information on the safety of a potential new medicine or vaccine (which we also test in Phase I and Phase II trials) and prove its efficacy.

Filed filed
 Following a successful Phase III trial, we file the product for approval by the regulatory authorities.

Approval approval
 Only when approval is granted can we begin to market the medicine or vaccine.

orange line



cardiovascular
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Arixtra Treatment of acute coronary syndrome Approved
Avandamet XR Type 2 diabetes - extended release Phase 3
Avandia + simvastatin Type 2 diabetes Phase 3
Coreg CR* + ACE inhibitor Hypertension - fixed dose combination Phase 3
Volibris (ambrisentan)* Pulmonary arterial hypertension Filed
icon >Back to top
white line
infectious diseases
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Altabax Bacterial skin infection Approved
ApprovedBack to top
white line
musculoskeletal
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Avodart Reduction in the risk of prostate cancer Phase 3
Avodart + alpha blocker Benign prostatic hyperplasia - fixed dose combination Phase 3
belimumab* Systemic lupus erythematosus Phase 3
Bosatria Hypereosinophilic syndrome Phase 3
Entereg/Entrareg* 1. Post operative ileus Filed
2. Opioid-induced bowel dysfunction Phase 3
ofatumumab Rheumatoid arthritis Phase 3
icon >Back to top
white line
neurosciences
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Lamictal XR Epilepsy - partial generalised tonic-clonic seizures, once-daily Filed
Lunivia* Sleep disorders Filed
ReQuip Modutab/XL* Parkinson's disease - once-daily controlled release formulation Approved
rosiglitazone XR Alzheimer's disease Phase 3
Treximet* Migraine - fixed dose combination Filed
1838262 (XP13512)* Restless legs syndrome Phase 3
icon >Back to top
white line
oncology
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Armala (pazopanib) Renal cell cancer and inflammatory breast cancer Phase 3
elesclomol* Metastatic melanoma Phase 3
ofatumumab* 1. Refractory chronic lymphocytic leukaemia Phase 3
2. Refractory follicular lymphoma Phase 3
Promacta/Revolade* 1.Short-term idiopathic thrombocytopenia Filed
2. Hepatitis C associated thrombocytopenia Phase 3
Rezonic/Zunrisa (casopitant) Chemotherapy-induced & postoperative nausea & vomiting Phase 3
Tykerb + Armala Inflammatory breast cancer Phase 3
Tykerb/Tyverb 1. Breast cancer Approved
2. Head & neck cancers Phase 3
icon >Back to top
white line
respiratory
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Avamys/Veramyst Allergic rhinitis Approved
icon >Back to top
white line
vaccines
Compound Indication Image showing indivcators, Phase 3, Filed and Approved
Cervarix* Human papilloma virus infection prophylaxis Approved
Flu pandemic/pre pandemic Pandemic influenza prophylaxis Filed
Hib-MenCY-TT Neisseria meningitis groups C & Y disease & Haemophilus influenzae type b disease prophylaxis Phase 3
MAGE-A3 Treatment of non-small cell lung cancer Phase 3
MenACWY-TT Neisseria meningitis groups A, C, W & Y disease prophylaxis Phase 3
New generation flu vaccine Seasonal influenza prophylaxis for the elderly Phase 3
Synflorix Streptococcus pneumoniae & non-typable Haemophilus influenzae disease prophylaxis for children Filed
>Back to top
white line Includes 2007 launches, most advanced status shown.

* In-license or other alliance relationship with third party.

Brand names appearing in italics are trademarks either owned by and/or licensed to GlaxoSmithKline or associated companies, with the exception of Entereg, a trademark of Adolor Corporation in the USA, which is used in certain countries under license by the Group.

Click here for a printer friendly version Print-friendly >Back to top
image